457 related articles for article (PubMed ID: 29021469)
1. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
Ishiguro K; Hayashi T; Yokoyama Y; Aoki Y; Onodera K; Ikeda H; Ishida T; Nakase H
Intern Med; 2018 Mar; 57(6):783-788. PubMed ID: 29021469
[TBL] [Abstract][Full Text] [Related]
2. Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis.
Miyazaki K; Suzuki K
Intern Med; 2018 Mar; 57(6):775-776. PubMed ID: 29321425
[No Abstract] [Full Text] [Related]
3. Differential diagnosis of localized and systemic amyloidosis based on coagulation and fibrinolysis parameters.
Suga N; Miura N; Kitagawa W; Morita H; Banno S; Imai H
Amyloid; 2012 Jun; 19(2):61-5. PubMed ID: 22417630
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
Arahata M; Takamatsu H; Morishita E; Kadohira Y; Yamada S; Ichinose A; Asakura H
Int J Hematol; 2020 Apr; 111(4):550-558. PubMed ID: 31897889
[TBL] [Abstract][Full Text] [Related]
5. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
6. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
7. The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis.
Shimazaki C; Matsui-Maegawa S; Kimoto-Matsumura Y; Ota-Kuwabara S; Ide D; Fuchida SI; Hatsuse M
Br J Haematol; 2023 Sep; 202(6):1209-1212. PubMed ID: 37424146
[No Abstract] [Full Text] [Related]
8. Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension.
Jinnin M; Ihn H; Yamane K; Asano Y; Yazawa N; Tamaki K
Rheumatology (Oxford); 2003 Feb; 42(2):240-3. PubMed ID: 12595617
[TBL] [Abstract][Full Text] [Related]
9. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N; Nguyen-Khoa T; Alyanakian MA
Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
[TBL] [Abstract][Full Text] [Related]
10. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
[TBL] [Abstract][Full Text] [Related]
11. [The clinical significance of serum free light chain in primary systemic amyloidosis].
Zhai YP; Song P; Li F; Liu HN; Yu YP; Zhou XG; Shi P; An ZM; Zhou X; Zhang CN
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):404-7. PubMed ID: 21624224
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma.
Kobayashi H; Abe Y; Miura D; Narita K; Kitadate A; Takeuchi M; Matsue K
Jpn J Clin Oncol; 2019 Feb; 49(2):195-198. PubMed ID: 30608548
[TBL] [Abstract][Full Text] [Related]
13. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
14. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
15. Management of the elderly patient with AL amyloidosis.
Nuvolone M; Milani P; Palladini G; Merlini G
Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
[TBL] [Abstract][Full Text] [Related]
17. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis.
Gatt ME; Kaplan B; Yogev D; Slyusarevsky E; Pogrebijski G; Golderman S; Kukuy O; Livneh A
Br J Haematol; 2018 Jul; 182(1):86-92. PubMed ID: 29767409
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms.
Matsuda M; Katoh N; Ikeda S
Intern Med; 2014; 53(5):403-12. PubMed ID: 24583427
[TBL] [Abstract][Full Text] [Related]
19. Multiple Myeloma Light Chain Amyloidosis Presenting as Hepatic Failure.
Elgouhari H; Ahmed K; Niazi M; Huntington MK
S D Med; 2018 Mar; 71(3):112-115. PubMed ID: 29991097
[TBL] [Abstract][Full Text] [Related]
20. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis.
Zhou FD; Zhang LX; Yao Y; Wang SX; Zou WZ; Liu G; Chen M; Zhao MH
Am J Med Sci; 2013 Jan; 345(1):18-21. PubMed ID: 22627261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
